cilostazol has been researched along with Acute Coronary Syndrome in 13 studies
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "In this prospective study, 1,212 patients with acute coronary syndromes were randomly assigned to receive either standard dual-antiplatelet treatment with aspirin and clopidogrel (n = 608) or triple-antiplatelet therapy with the addition of a 6-month course of cilostazol (n = 604) after successful PCI." | 9.14 | Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. ( Han, Y; Jing, Q; Li, Y; Shu, Q; Tang, X; Wang, D; Wang, S; Wang, Z, 2009) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes." | 8.89 | Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel? ( Bangalore, S; Dinicolantonio, JJ; Lavie, CJ; Meier, P; Niazi, AK; O'Keefe, JH, 2013) |
| "Cilostazol 100 mg b." | 6.75 | Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. ( Ahluwalia, J; Bhalla, A; Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP, 2010) |
| "Cilostazol is a specific and strong inhibitor of phosphodiesterase (PDE) type III which can suppress the platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels." | 5.62 | Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome. ( Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y, 2021) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "In this prospective study, 1,212 patients with acute coronary syndromes were randomly assigned to receive either standard dual-antiplatelet treatment with aspirin and clopidogrel (n = 608) or triple-antiplatelet therapy with the addition of a 6-month course of cilostazol (n = 604) after successful PCI." | 5.14 | Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. ( Han, Y; Jing, Q; Li, Y; Shu, Q; Tang, X; Wang, D; Wang, S; Wang, Z, 2009) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes." | 4.89 | Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel? ( Bangalore, S; Dinicolantonio, JJ; Lavie, CJ; Meier, P; Niazi, AK; O'Keefe, JH, 2013) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is a well-established standard of care for patients with acute coronary syndromes." | 4.87 | Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? ( Moliterno, DJ; Rajan, L, 2011) |
| "Cilostazol 100 mg b." | 2.75 | Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. ( Ahluwalia, J; Bhalla, A; Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP, 2010) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "Cilostazol is a specific and strong inhibitor of phosphodiesterase (PDE) type III which can suppress the platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels." | 1.62 | Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome. ( Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, Y | 1 |
| Wang, Z | 2 |
| Wu, H | 1 |
| Li, X | 1 |
| Chen, J | 1 |
| Lv, Q | 1 |
| Vieira, MS | 1 |
| Niazi, AK | 1 |
| Dinicolantonio, JJ | 1 |
| Lavie, CJ | 1 |
| O'Keefe, JH | 1 |
| Meier, P | 1 |
| Bangalore, S | 1 |
| Lee, K | 1 |
| Yoo, SY | 1 |
| Suh, J | 1 |
| Park, KH | 1 |
| Park, Y | 1 |
| Tantry, US | 1 |
| Park, KS | 1 |
| Han, SH | 1 |
| Kang, WC | 1 |
| Shin, DH | 1 |
| Lee, C | 1 |
| Choi, SW | 1 |
| Lee, JH | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Jeong, MH | 1 |
| Ahn, Y | 1 |
| Kubica, J | 1 |
| Gurbel, PA | 1 |
| Park, JH | 2 |
| Jeong, YH | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Han, Y | 1 |
| Li, Y | 2 |
| Wang, S | 1 |
| Jing, Q | 1 |
| Wang, D | 1 |
| Shu, Q | 1 |
| Tang, X | 1 |
| Pattanaik, S | 1 |
| Malhotra, S | 1 |
| Sharma, YP | 1 |
| Ahluwalia, J | 1 |
| Bhalla, A | 1 |
| Pandhi, P | 1 |
| Ahn, CM | 1 |
| Hong, SJ | 1 |
| Kim, JS | 1 |
| Lim, DS | 1 |
| Rajan, L | 1 |
| Moliterno, DJ | 1 |
| Ferreiro, JL | 1 |
| Cequier, AR | 1 |
| Angiolillo, DJ | 1 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 1 |
| Guan, SY | 1 |
| Han, YL | 1 |
| Guo, L | 1 |
| Yang, BS | 1 |
| Wang, SL | 1 |
| Jing, QM | 1 |
| Wang, XZ | 1 |
| Ma, YY | 1 |
| Liu, XD | 1 |
| Geng, DF | 1 |
| Liu, M | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Deng, J | 1 |
| Wang, JF | 1 |
6 reviews available for cilostazol and Acute Coronary Syndrome
| Article | Year |
|---|---|
Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clinical Trials as Topic; Clopidogrel; Drug Therapy, C | 2013 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug | 2011 |
Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cilostazol; Clopidogrel; Diabetes Complicati | 2010 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
5 trials available for cilostazol and Acute Coronary Syndrome
| Article | Year |
|---|---|
Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammati
Topics: Acute Coronary Syndrome; Aged; Cilostazol; Drug Administration Schedule; Female; Humans; Inflammatio | 2015 |
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Ci | 2009 |
Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Double-Blind Method; Drug Th | 2010 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
[Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation].
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therap | 2012 |
2 other studies available for cilostazol and Acute Coronary Syndrome
| Article | Year |
|---|---|
Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; China; Cilostazol; Clopido | 2021 |
Tailoring antiplatelet therapy in acute coronary syndromes: the thin red line.
Topics: Acute Coronary Syndrome; Cilostazol; Humans; Phosphodiesterase 3 Inhibitors; Platelet Aggregation In | 2013 |